Close Menu

The Wall Street Journal has a commentary piece from Sidney Taurel, chairman and CEO of Eli Lilly and Company, on a recent flare-up over a drug candidate in clinical trials. The heart-attack drug, prasugrel, was in two trials that were halted pending review of a few cases of adverse effects. Taurel says the media coverage that followed this not only got the story wrong, but resulted in cutting Lilly's market cap by "about $6 billion."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.